Knowledge · Natural Compounds

Taurine

Taurine is a sulfonic acid produced by the body itself; human studies show benefits for blood pressure, vascular function and blood sugar, but the data on endurance performance are uncertain.

Last updated:

We evaluated 153 human studies on Taurine, including 51 randomised controlled trials and 21 meta-analyses or systematic reviews; the controlled studies include 1,885 participants in total. As of 8 October 2026.

This page as PDF · Summary

1. What Is Taurine? Occurrence, Origin and Forms

Taurine is a sulfur-containing compound that chemically belongs to the sulfonic acids and, unlike the proteinogenic amino acids, is not incorporated into proteins. The body produces it from cysteine and methionine itself and takes most of it in through animal foods. Taurine is known as an additive in energy drinks and infant formula, and as a dietary supplement it is offered in powder or capsule form.

Taurine occurs in animal tissues, especially abundantly in fish and seafood, and also in meat and milk. In the human body it is found in many tissues, among others in cardiac and skeletal muscle, in the retina and in the brain, and it is present in breast milk.

For dietary supplements, taurine is produced industrially, mostly by chemical synthesis. Studies examine above all oral forms as a single substance, alongside taurine-containing drinks, eye drops, and taurine in parenteral nutrition solutions and in infant formula.

Forms and Preparations Studied

  • Taurine as a single substance, taken as powder or capsules
  • Taurine-containing soft drinks, usually together with caffeine, sugar and other additives (mixture)
  • Taurine eye drops for application to the eye
  • Taurine in parenteral nutrition solutions (infusion)
  • Taurine in infant formula
  • Taurine in dietary supplements with other substances (combination product)

Not covered on this page:

  • Energy drinks as a beverage category, whose effect cannot be attributed to taurine alone
  • Caffeine and other individual ingredients of energy drinks
  • Homotaurine, known as the drug acamprosate, a different molecule
  • Bile acid conjugates such as taurocholic acid, in which taurine is bound

2. What Does Taurine Do? Results by Area

AreaResult in controlled studiesStrength of evidenceStudiesParticipants
Physical performancemixedhigh5 meta-analyses · 17 controlled · 10 other277
Heart and circulationmostly improvedhigh3 meta-analyses · 12 controlled · 9 other296
Blood sugar and metabolismmostly improvedhigh5 meta-analyses · 5 controlled · 9 other251
Blood pressuremostly improvedmoderate7 meta-analyses · 1 controlled · 3 other0
Nerves and brainmostly no differencelow4 meta-analyses · 5 controlled · 21 other128
Aging and longevitymostly improvedlow0 meta-analyses · 1 controlled · 5 other24
Eye and retinareviews onlylow1 meta-analyses · 0 controlled · 5 other0
Other investigationsmostly improvedhigh9 meta-analyses · 38 controlled · 41 other1,484

How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.

3. What the Studies Show in Detail

Taurine and Physical Performance: Human Studies

A meta-analysis found small performance benefits after a single taurine dose, especially for endurance and strength, with low certainty of evidence 5. In two randomized controlled trials in humid heat, young adults with taurine lasted longer, but only at certain doses 5657. Another meta-analysis found better jumping performance than with placebo 16, and a randomized controlled trial found more anaerobic performance in speed skaters 43. After eccentric strength training, strength recovered better in two randomized controlled trials than with placebo 5164. A meta-analysis found less lactate dehydrogenase after exertion, and a benefit for muscle pain only at a late time point 10; a randomized controlled trial also showed less muscle soreness 51. A small controlled trial in runners found lower AST and inflammation values, but no difference in creatine kinase 76. These are contrasted by results with no difference: a meta-analysis found no benefit in maximal oxygen uptake 16, and two controlled trials found none in time to exhaustion 5574. The findings come predominantly from small, short studies in young, trained men; the intake duration ranged from an acute single dose to several weeks. In two randomized controlled trials, the combination of taurine and caffeine improved individual performance values, while taurine alone did not 4154. In a third study, the combination brought no benefit in repeated sprints 58. It remains open whether the effects persist in women, older people and over longer periods.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
1 Wang et al. 2026systematic review · 1,030 participantsTaurine supplementation; optimal 3,000 mg daily; vs. Control in included trialsexercise capacity: improved
5 Deng et al. 2025meta-analysis · 308 participantsAcute single taurine dose, capsule or beverage formulation; commonly used 1-6 g range; single ingestion, about 1 h before exercise; vs. control/placebo in randomized trialsoverall performance: improved (g = 0.25, 95% CI [0.10, 0.39]); aerobic endurance, strength/power, agility/coordination: improved; anaerobic capacity and muscular endurance: unclear
10 Dehghani et al. 2025meta-analysis · 165 participantsTaurine supplementation (form/dose not reported); vs. Placebo or control groupCreatine kinase post-exercise: improved (WMD = −7.91 IU/L, 95 % CI: −122.21 to 138.04); Creatine kinase after 24 h: improved (WMD = −78.28 IU/L, 95 % CI: −211.55 to 54.99); Lactate dehydrogenase post-exercise to 48 h: improved
16 Buzdağlı et al. 2022meta-analysisTaurine supplement; vs. Placebo groupVertical jump performance: improved (MD =3.60; 95% CI 2.32 to 4.89, p <0.00001); Countermovement jump performance: improved (MD = 8.50; 95% CI 4.78 to 12.22, p <0.00001); VO2max: no difference (MD = −0.54 ml/kg/min; 95% CI −6.84 to 5.75, p=0.87)
21 Kurtz et al. 2021systematic reviewTaurine as sole ingredient, oral intake; <1 g to 6 g, acute or chronic; acute 10-15 min to 2 h before exercise; chronic 7 days to 8 weeks; vs. no uniform control, 19 included studiesVO2max: improved; time to exhaustion (TTE), n = 5 articles: improved (n = 5 articles); 3 or 4 km time-trial, n = 2 articles: improved (n = 2 articles)
41 Köse et al. 2026randomised controlled · 32 participantsTaurine 10 mg/kg oral, alone and with caffeine 2 mg/kg; Taurine 10 mg/kg; caffeine 2 mg/kg; acute single dose; vs. placebo and caffeine alone, double-blind randomized crossoverhandgrip strength: no difference (p = 0.044; d = 0.51); average power: no difference (p = 0.001; d = 0.91); peak power: no difference (p > 0.05)
43 Buzdağlı et al. 2023randomised controlled · 30 participantsoral taurine; single 6 g dose; 60 minutes before testing, 72-hour washout; vs. placebo 6 gpeak power output in Wingate test: improved (Δ% = 13.41, p < 0.001, d = 1.71); mean power output in Wingate test: improved (Δ% = 3.95, p = 0.002, d = 1.04); minimum power output in Wingate test: improved (Δ% = 7.89, p = 0.034, d = 0.48)
48 De et al. 2021randomised controlled · 24 participantsTaurine supplementation or placebo; 3 g taurine; 8 weeks; vs. Tau alone, Ex alone, TauEx, placeboResting energy expenditure: no difference

Further studies in this area: 51 52 54 55 56 57 58 60 63 64 74 76 77 78 81 97 118 120 122 123 124 129 143 144

Taurine, Heart and Circulation: Human Studies

In three randomized controlled trials, vascular function or arterial stiffness improved more than with placebo, including in people with diabetes 466566. One meta-analysis found a lower heart rate and, in heart failure, a higher ejection fraction and a better NYHA class 3. A systematic review, by contrast, found no confirmed difference in ejection fraction and stroke volume in heart failure 18. The findings come predominantly from small, short studies; the optimal dose and long-term effect remain open. A controlled trial with a mixture of caffeine and taurine found no difference in skin blood flow 75.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
3 Tzang et al. 2024meta-analysis · 808 participantsTaurine (form not specified); not reported, meta-regression by total dose; not reported; vs. control groupheart rate: improved (WMD = -3.579 bpm, 95% CI = -6.044 to -1.114, p = 0.004); left ventricular ejection fraction: improved (WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004); NYHA functional classification: improved (WMD: -0.403, 95% CI: -0.522 to -0.283, p < 0.001)
13 Nie et al. 2026meta-analysisOral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trialsTriglycerides: improved (MD, -14.42 mg/dL; 95% CI, -23.60 to -5.25); Total cholesterol: improved (MD, -12.41 mg/dL; 95% CI, -19.10 to -5.71); LDL cholesterol: improved (MD, -5.08 mg/dL; 95% CI, -8.35 to -1.81)
18 McGurk et al. 2022systematic reviewTaurine supplementation; formulations: tablet, capsule, drink, powder; 500 mg to 6 g per day; 2 to 48 weeks; vs. no uniform comparator; studies heterogeneousejection fraction in all-cause heart failure: no difference (P<0.05); stroke volume in all-cause heart failure: no difference; diastolic and systolic function, exercise capacity, haemodynamic parameters: unclear
25 Moludi et al. 2022randomised controlled · 120 participantsTaurine 1 g versus placebo, plus low-calorie diet; 1 g taurine three times per day; eight weeks; vs. placebo plus low-calorie dietendothelial markers ICAM-1, VCAM, MMP-9: improved
36 Samadpour et al. 2021randomised controlled · 40 participantsoral taurine supplementation; 8 weeks; vs. TRX+placebo, taurine alone, controlHDL cholesterol: improved; total cholesterol: improved; LDL cholesterol: no difference
45 Ra et al. 2019randomised controlled · 29 participantstaurine supplement vs. placebo; 6 g/day; 2 weeks before and 3 days after exercise; vs. placebo groupRelative and absolute flow-mediated dilation at rest: improved (significantly increased both relative and absolute FMDs); FMD reduction 96 h after resistance exercise: no difference (does not affect resistance exercise-induced reduction in FMD)
46 Ra et al. 2016randomised controlled · 29 participantsoral taurine, placebo; 2.0 g taurine or placebo, 3 times per day; 14 days before, on day of, and 3 days after exercise; vs. placebo-controlled, double-blind, randomizedcarotid-femoral pulse wave velocity (cfPWV): improved (significantly attenuated)
54 Karayigit et al. 2021randomised controlled · 17 participantsTaurine alone, caffeine alone, caffeine+taurine, placebo; 1 g taurine; 6 mg/kg caffeine; ingested 60 min before 30-s Wingate test; vs. placebo and caffeine alone or taurine aloneheart rate: no difference (p > 0.05)

Further studies in this area: 56 60 65 66 70 74 77 79 97 115 119 120 139 142 145 146

Taurine, Blood Sugar and Metabolism: Human Studies

Several meta-analyses found lower fasting blood sugar with oral taurine, and in people with diabetes also lower long-term blood sugar and less insulin resistance 12813. In two randomized controlled trials in type 2 diabetes, fasting blood sugar, insulin and insulin resistance decreased more than with placebo 3132. A third study found a benefit only for insulin and insulin resistance, not for blood sugar 25. For blood lipids, two meta-analyses found lower triglycerides 222 and a randomized controlled trial found lower total and LDL cholesterol 31. A meta-analysis in diabetes and another randomized controlled trial found no difference in blood lipids 825. For inflammatory markers, oxidative stress and CAT activity, a randomized controlled trial found improvements, while it remained without difference for IL-6 and TAC 29. Taurine had no independent influence on resting metabolic rate in two randomized controlled trials with training in obese women 4849.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
1 Wang et al. 2026systematic review · 1,030 participantsTaurine supplementation; optimal 3,000 mg daily; vs. Control in included trialsHbA1c, fasting glucose, fasting insulin, HOMA-IR: improved
2 Tzang et al. 2024meta-analysis · 1,024 participantsTaurine supplementation (powder/capsule); 0.5 to 6 g per day; 5 to 365 days; vs. Control groupFasting blood glucose: improved (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018); Triglycerides: improved (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001); HDL cholesterol: no difference (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155)
8 Tao et al. 2022meta-analysis · 209 participantsTaurine supplement; vs. Control groupHbA1c: improved (SMD -0.41[95% CI: -0.74, -0.09], p = 0.01); Fasting Blood Sugar: improved (SMD - 1.28[95% CI: -2.42, -0.14], p = 0.03); HOMA-IR: improved (SMD - 0.64[95% CI: -1.22, -0.06], p = 0.03)
13 Nie et al. 2026meta-analysisOral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trialsFasting blood glucose: improved (MD, -5.90 mg/dL; 95% CI, -9.65 to -2.15); Glycated hemoglobin A1c: improved (MD, -0.21%; 95% CI, -0.37 to -0.05); Fasting insulin: improved (SMD, -0.55; 95% CI, -0.78 to -0.32)
22 Guan et al. 2020meta-analysisTaurine supplementation (oral intake); 0.5 to 6 g/day; 15 days to 6 months; vs. Control group (placebo)Total cholesterol: improved (WMD: -10.87 mg/dl; 95%CI, -16.96 to -4.79); Triglycerides: improved (WMD: -13.05 mg/dl; 95%CI, -25.88 to -0.22); Fasting blood glucose: no difference (WMD: 0.06 mg/dl)
25 Moludi et al. 2022randomised controlled · 120 participantsTaurine 1 g versus placebo, plus low-calorie diet; 1 g taurine three times per day; eight weeks; vs. placebo plus low-calorie dietserum insulin and HOMA-IR: improved; fasting blood glucose and glycated hemoglobin: no difference
31 Esmaeili et al. 2021randomised controlled · 46 participantstaurine supplement vs. placebo; 3,000 mg/day; 8 weeks; vs. placebo, double-blind randomizedfasting blood sugar: improved (p=0.01); glycated hemoglobin: improved (p=0.04); insulin: improved (p=0.03)
32 Maleki et al. 2020randomised controlled · 45 participantstaurine supplementation; 3000 mg daily; 8 weeks; vs. placebo (crystalline microcellulose)fasting blood sugar (FBS): improved (p = 0.01); insulin: improved (p = 0.01); HOMA-IR: improved (p = 0.003)

Further studies in this area: 36 69 112 118 120 130 135 136 137 142 146

Taurine and Blood Pressure: Human Studies

Several meta-analyses found lower systolic and diastolic blood pressure with orally ingested taurine, in healthy individuals as well as in people with metabolic, liver or heart diseases 23121322. A randomized controlled trial in type 2 diabetes also found lower systolic blood pressure than with placebo 66. A meta-analysis in people with diabetes mellitus, by contrast, found no difference in blood pressure 8. The strength of evidence is moderate; the studies differ in dose, intake duration and number of participants.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
1 Wang et al. 2026systematic review · 1,030 participantsTaurine supplementation; optimal 3,000 mg daily; vs. Control in included trialsblood pressure: improved
2 Tzang et al. 2024meta-analysis · 1,024 participantsTaurine supplementation (powder/capsule); 0.5 to 6 g per day; 5 to 365 days; vs. Control groupSystolic blood pressure: improved (WMD = -3.999 mmHg, 95% CI = -7.293 to -0.706, p = 0.017); Diastolic blood pressure: improved (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002)
3 Tzang et al. 2024meta-analysis · 808 participantsTaurine (form not specified); not reported, meta-regression by total dose; not reported; vs. control groupsystolic blood pressure: improved (WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017); diastolic blood pressure: improved (WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007)
8 Tao et al. 2022meta-analysis · 209 participantsTaurine supplement; vs. Control groupBlood pressure: no difference
12 Waldron et al. 2018meta-analysis · 103 participantsorally administered isolated taurine; 1 to 6 g/day; 1 day to 12 weeks; vs. control (not further described)systolic blood pressure: improved (Hedges' g = - 0.70, 95% CI - 0.98 to - 0.41, P < 0.0001); diastolic blood pressure: improved (Hedges' g = - 0.62, 95% CI - 0.91 to - 0.34, P < 0.0001)
13 Nie et al. 2026meta-analysisOral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trialsSystolic blood pressure: improved (MD, -4.38 mmHg; 95% CI, -7.26 to -1.50); Diastolic blood pressure: improved (MD, -2.54 mmHg; 95% CI, -3.97 to -1.11)
22 Guan et al. 2020meta-analysisTaurine supplementation (oral intake); 0.5 to 6 g/day; 15 days to 6 months; vs. Control group (placebo)Systolic blood pressure: improved (WMD: -4.67 mm Hg; 95%CI, -9.10 to -0.25); Diastolic blood pressure: improved (WMD: -2.90 mm Hg; 95%CI, -4.29 to -1.52)
66 Li et al. 2025randomised controlledTaurine (oral); 2.4 g/day; 12 weeks; vs. PlaceboSystolic blood pressure: improved

Further studies in this area: 112 137 145

Taurine, Nerves and Brain: Human Studies

For cognitive performance, a meta-analysis and two systematic reviews found no confirmed advantage of taurine 146. A randomized controlled trial found in traumatic brain injury with taurine in addition to tube feeding a better level of consciousness than without taurine 42. After liver transplantation, delirium occurred less frequently with taurine in a randomized controlled trial than with placebo 68. Combination products with vitamins or caffeine do not allow statements about taurine alone 3340. Populations, doses and intake durations are very different, and for healthy adults null findings predominate.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
1 Wang et al. 2026systematic review · 1,030 participantsTaurine supplementation; optimal 3,000 mg daily; vs. Control in included trialsneurocognition: no difference
4 Cao et al. 2025meta-analysis · 402 participantstaurine, alone or combined with exercise training or therapeutic drugs; vs. exercise training alone, therapeutic drugs alone, placebocognitive scores: no difference; Mini-Mental State Examination (taurine plus drugs vs. drugs alone): no difference (WMD = 3.09, 95% CI: 2.29-3.90)
6 Moore et al. 2026systematic review · 244 participantsoral taurine, acute single dose; sometimes combined with caffeine; typically 1-3 g, up to ~50 mg/kg; acute single dose; vs. placebo or control; sometimes taurine plus caffeinecognitive performance: no difference; mood and well-being: unclear
9 Verner et al. 2007systematic review · 189 participantsTaurine supplementation, mostly enteral with formula milk, one trial parenteral; Neonatal period until 3–4 months chronological age; vs. Taurine supplementation versus no supplementationLong-term growth or neurological outcomes: unclear (no data)
11 Pedregosa et al. 2026review · 130 participantstaurine (single agent, oral intake); vs. no taurine control arm in this reviewassociation between dietary taurine intake and depression: no difference; antidepressant- and anxiolytic-like effects in animal models: improved
41 Köse et al. 2026randomised controlled · 32 participantsTaurine 10 mg/kg oral, alone and with caffeine 2 mg/kg; Taurine 10 mg/kg; caffeine 2 mg/kg; acute single dose; vs. placebo and caffeine alone, double-blind randomized crossovercognitive performance: no difference (p > 0.05)
42 Vahdat et al. 2021randomised controlled · 32 participantstaurine added to standard enteral meal vs. standard enteral meal alone; 30 mg/kg/day taurine; 14 days; vs. taurine plus standard enteral meal vs. standard enteral meal aloneGlasgow coma scale: improved (p = 0.03)
58 Liu et al. 2025randomised controlled · 16 participantsTaurine 50 mg/kg, caffeine 5 mg/kg, taurine+caffeine, placebo (maltodextrin 5 mg/kg); Taurine 50 mg/kg; caffeine 5 mg/kg; Single dose before exhaustion and sprint tests in hypoxia; vs. Placebo (maltodextrin 5 mg/kg)Stroop Test response time: no difference

Further studies in this area: 68 72 86 94 96 97 100 103 104 107 108 110 112 113 116 120 121 125 128 131 139 142

Taurine, Aging and Longevity: Human Studies

A randomized controlled trial with older women found higher levels of the antioxidant enzyme SOD with taurine than with placebo 47. The oxidative marker malondialdehyde rose only in the placebo group 47. The strength of evidence is low, since only one controlled trial with a small number of participants is available. One review sees a benefit of taurine supplementation for healthy aging 118, another for protection against mitochondrial defects 139. A further review suggests that a mixture of taurine and glutamine together with training could counteract muscle loss in old age 121.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
47 Abud et al. 2022randomised controlled · 24 participantsTaurine or placebo (1.5 g starch); 1.5 g daily; 16 weeks; vs. Placebo group (1.5 g starch)superoxide dismutase (SOD): improved (SOD levels also were higher than in the GC group); glutathione reductase: no difference (decreased regardless of the intervention); malondialdehyde: improved (increased only in the GC participants)
81 Marcangeli et al. 2025cross-sectional study · 137 participantsno preparation; measurement of circulating taurine; vs. no comparison; cross-sectional analysis by age and activityassociation of taurine with age: no difference
99 Frascatani et al. 2026cohort studyTaurine (serum levels, no administration); median 45 months follow-up; vs. IBD patients vs. healthy controlsAge-related taurine decline in healthy controls: no difference
118 Beine et al. 2026reviewTaurine supplementation; 1-6 g per day; vs. no comparator arm reportedhealthy aging: improved
121 Chen et al. 2026reviewtaurine and glutamine supplementation, partly with exercise regimensmuscle mass, strength and neuromuscular efficacy: unclear
139 Jong et al. 2021reviewTaurine supplementationProtection against mitochondrial defects: improved

Taurine, Eye and Retina: Human Studies

A review suggests that taurine as a dietary supplement could alleviate visual fatigue; controlled studies with taurine alone on the eye are still pending 15. A randomized controlled trial with 43 healthy participants found with a combination product of taurine with vitamin C, vitamin E, zinc, lutein/zeaxanthin, selenium, aronia extract and omega-3 fatty acids more favorable values for retinal artery diameter, erythrocyte velocity in retinal vessels and retinal blood flow 35; since no arm here received taurine alone, the effect cannot be attributed to the taurine. The strength of evidence is low, because no controlled study has tested taurine alone on the eye. It remains open whether taurine alone acts on the eye.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
15 Duan et al. 2023systematic reviewTaurine (endogenous sources, diet, supplements)Visual fatigue: improved
87 Hiller et al. 2025case-control study · 23 participantsNo taurine administration; vitreous metabolite measurement; vs. DR groups versus controlsvitreous taurine in NPDR: worsened (p < 0.01)
95 Horvath et al. 2016case series · 2 participantsL-taurine supplementation, oral; vs. Before-after under vigabatrin therapyElectroretinogram changes: improved
101 Ullah et al. 2026case seriesNo taurine administration; SLC6A6 variants and plasma taurine assessed; vs. Heterozygous carriers and healthy controlsTaurine transport in HEK-293 cells and patient-derived fibroblasts: worsened (complete loss of taurine transport)
133 García-Ayuso et al. 2024reviewTaurine (review, no primary study)retinal taurine deficiency: worsened; taurine administration as neuroprotection: unclear
138 Castelli et al. 2021reviewTaurine (supplementation)Slowing of progression of degenerative retinal diseases: improved; Improvement of retinal reduced glutathione, malondialdehyde, superoxide dismutase, and catalase: improved; Antiapoptotic effects: improved

Taurine: Further Outcomes in Studies

Inflammatory markers decreased more strongly than with placebo in two randomized controlled trials 2761, markers of oxidative stress in two others 3846. Total and LDL cholesterol decreased more strongly than in the comparison group in two randomized controlled trials 3269, liver values in two others 2438. For clinical endpoints, several controlled studies found advantages, for example for muscle cramps in chronic liver disease 30, in ventilated children 27 and after liver transplantation 24. These are contrasted by results without difference, for example for anthropometry and body weight 485969 as well as for several inflammatory and oxidation markers 445176. Combination products with N-acetylcysteine 2628, with caffeine 54 or with numerous other substances 67 do not allow conclusions about taurine alone.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
1 Wang et al. 2026systematic review · 1,030 participantsTaurine supplementation; optimal 3,000 mg daily; vs. Control in included trialstotal cholesterol, triglycerides, LDL: improved; inflammatory markers CRP, TNF-α, IL-6: improved; oxidative stress (malondialdehyde): improved
7 Cao et al. 2018meta-analysis · 216 participantsTaurine supplementation (form not reported); vs. control without taurinelength gain: worsened (WMD:-0.18; P < 0.001); plasma glycine: worsened (WMD:-106.71; P = 0.033); plasma alanine: worsened (WMD:-229.30; P = 0.002)
8 Tao et al. 2022meta-analysis · 209 participantsTaurine supplement; vs. Control groupSerum lipids: no difference; Body composition: no difference
9 Verner et al. 2007systematic review · 189 participantsTaurine supplementation, mostly enteral with formula milk, one trial parenteral; Neonatal period until 3–4 months chronological age; vs. Taurine supplementation versus no supplementationIntestinal fat absorption: improved (weighted mean difference 4.0 (95% confidence interval 1.4, 6.6) percent of intake); Rate of weight gain: no difference (weighted mean difference -0.25 (95% confidence interval -1.16, 0.66) grams/kilogram/day); Change in length: no difference (weighted mean difference 0.37 (95% confidence interval -0.23, 0.98) millimetres/week)
13 Nie et al. 2026meta-analysisOral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trialsAspartate aminotransferase: improved (MD, -9.65 U/L; 95% CI, -17.39 to -1.90); Alanine aminotransferase: improved (MD, -8.26 U/L; 95% CI, -14.81 to -1.70); C-reactive protein: improved (SMD, -1.26; 95% CI, -2.01 to -0.52)
14 Roberts et al. 2025systematic reviewTaurine supplementation; vs. PlaceboCramp frequency, severity, and duration: improved
17 Faghfouri et al. 2022meta-analysisTaurine supplementation; various doses (dose-response analysis); various durations, 56 days more beneficial; vs. Control groupMalondialdehyde (MDA): improved (SMD = -1.17 µmol/l; 95% CI: -2.08, - 0.26; P = 0.012); C-reactive protein (CRP): improved (SMD = -1.95 mg/l; 95% CI: -3.20, - 0.71; P = 0.002); Tumor necrosis factor-alpha (TNF-α): no difference (SMD = -0.18 pg/ml; 95% CI: -0.56, 0.21; P = 0.368)
19 Mirjalili et al. 2022systematic reviewTaurine among 22 other compounds; vs. Control without nephroprotective agent, not reportedNephroprotective effect during colistin exposure: improved

Further studies in this area: 20 22 23 24 25 26 27 28 29 30 31 32 34 36 37 38 39 42 44 46 48 49 50 51 53 54 56 57 59 61 62 63 64 67 69 71 73 74 76 78 80 82 83 84 85 88 89 90 91 92 93 94 96 98 99 101 102 105 106 108 109 110 111 114 115 117 118 120 121 123 126 127 132 134 135 140 141 142 143 144

4. How Is Taurine Dosed? Preparation, Dose and Duration in Studies

The studies predominantly used oral taurine as a single substance in powder or capsule form, sometimes as an acute single dose, sometimes over several weeks. Individual investigations used combination products with caffeine, vitamins or other substances. The doses and intake durations are shown in the table.

Preparation or formDoseDurationStudy
Oral L-taurine plus standard care1000 mg per day12 weeks23
Oral taurine supplementation vs. placebo2 g/dayTransplant day to day 3024
Taurine 1 g versus placebo, plus low-calorie diet1 g taurine three times per dayeight weeks25
Nefrosave®: NAC 150 mg + taurine 500 mgtwice daily180 days26
taurine or placebo capsules plus standard care30 mg/kg/day in divided dosesfrom PICU admission until PICU discharge27
NT arm: 500 mg taurine + 150 mg NAC; NP arm: 300 mg NAC + 50 mg pyridoxaminetwice daily, 500 mg taurine + 150 mg NAC per intake6 months, monthly assessment28
Taurine capsule (1000 mg) vs. placebo (crystalline microcellulose)1000 mg taurine three times daily8 weeks29
Oral taurine supplementation2 g taurine per day4 weeks per arm, crossover30
taurine supplement vs. placebo3,000 mg/day8 weeks31
taurine supplementation3000 mg daily8 weeks32
blend of taurine, vitamins B6, B9 and B12—four-week supplementation33
Oral taurine supplementation3 g/day12 weeks34
Dietary supplement containing taurine and other ingredients—14 days daily35
oral taurine supplementation—8 weeks36
oral taurine vs. placebo, double-blind randomized2 g per day in two doses, 6 h after chemotherapy6 months37

5. Is Taurine Safe? Side Effects in Studies

The included studies predominantly report no or only mild side effects, such as gastrointestinal complaints 232350. In a randomized controlled trial, mild adverse events occurred in some of the participants 23. In mice with a predisposition to lupus, supplemental taurine increased autoantibodies and kidney inflammation; whether this applies to people with lupus is open 111.

StudyReported side effects
2 Tzang et al. 2024No significant adverse effects versus control
3 Tzang et al. 2024no significant adverse effects versus controls
11 Pedregosa et al. 2026no serious adverse events in included human studies
12 Waldron et al. 2018no adverse events reported
14 Roberts et al. 2025Only pregabalin had significant side effects; no data for taurine
15 Duan et al. 2023Safety of consumption is reviewed
18 McGurk et al. 2022no significant safety concerns reported
23 Sasidharan et al. 202611.8% with taurine, all mild
26 Bhalla et al. 2026mild adverse events in five participants in the test arm
30 Vidot et al. 2018No adverse side effects associated with taurine supplementation
37 Islambulchilar et al. 2015adverse effects assessed by questionnaire; none specific reported
39 Islambulchilar et al. 2015side effects assessed by questionnaire, no numbers reported

6. What Remains Open: Limits of the Evidence

  • Most studies are small and short; women, older people and long-term endpoints are underrepresented.
  • For taurine eye drops, infusion solutions and infant formula, hardly any controlled findings are available.
  • Combination preparations with caffeine or other substances do not allow conclusions about taurine alone.
  • The optimal dose and intake duration are open for most endpoints.
  • For clinical endpoints such as heart failure or cognitive performance, the results are inconsistent.

7. Bottom Line: What Is Established About Taurine

Taurine is a sulfur-containing compound that the body produces itself and takes in through animal foods. Human studies show benefits for blood pressure, vascular function and blood sugar for oral taurine as a single substance; for physical performance they are small and uncertain. The findings come predominantly from small, short studies in young, trained men or in people with metabolic disorders. For healthy adults, null findings predominate in cognitive tests. For taurine eye drops, infusion solutions and infant formula, the data are thin. Combination preparations with caffeine or other substances do not allow any statement about taurine alone.

Frequently Asked Questions

How well has Taurine been studied in humans?

We evaluated 153 human studies on Taurine, including 51 randomised controlled trials and 21 meta-analyses or systematic reviews; the controlled studies include 1,885 participants in total. As of 8 October 2026.

Does Taurine help with physical performance? What the studies show

We evaluated 5 meta-analyses or systematic reviews, 17 controlled studies and 10 further studies; the controlled studies include 277 participants in total. Result of the controlled studies: mixed. Strength of evidence under our published rules: high. Sources: 151016

Does Taurine help with heart and circulation? What the studies show

We evaluated 3 meta-analyses or systematic reviews, 12 controlled studies and 9 further studies; the controlled studies include 296 participants in total. Result of the controlled studies: mostly improved. Strength of evidence under our published rules: high. Sources: 3131825

Does Taurine help with blood sugar and metabolism? What the studies show

We evaluated 5 meta-analyses or systematic reviews, 5 controlled studies and 9 further studies; the controlled studies include 251 participants in total. Result of the controlled studies: mostly improved. Strength of evidence under our published rules: high. Sources: 12813

Does Taurine help with blood pressure? What the studies show

We evaluated 7 meta-analyses or systematic reviews, one controlled study and 3 further studies. Result of the controlled studies: mostly improved. Strength of evidence under our published rules: moderate. Sources: 1238

Does Taurine help with nerves and brain? What the studies show

We evaluated 4 meta-analyses or systematic reviews, 5 controlled studies and 21 further studies; the controlled studies include 128 participants in total. Result of the controlled studies: mostly no difference. Strength of evidence under our published rules: low. Sources: 1469

Does Taurine help with aging and longevity? What the studies show

We evaluated one controlled study and 5 further studies; the controlled studies include 24 participants in total. Result of the controlled studies: mostly improved. Strength of evidence under our published rules: low. Sources: 478199118

Does taurine improve athletic performance?

A meta-analysis found small performance benefits after a single taurine dose, with low certainty of evidence 5. Other studies found no difference in maximal oxygen uptake or time to exhaustion 165574. The findings come predominantly from small, short studies in young, trained men.

How does taurine affect blood pressure?

Several meta-analyses found lower systolic and diastolic blood pressure with orally ingested taurine, in healthy people as well as in people with metabolic, liver or heart disease 23121322. A randomized controlled trial in type 2 diabetes also found lower systolic blood pressure than with placebo 66. A meta-analysis in people with diabetes mellitus, by contrast, found no difference in blood pressure 8. The strength of evidence is moderate.

Are there studies on taurine eye drops?

A review suggests that taurine as a dietary supplement could alleviate visual fatigue; controlled studies with taurine alone on the eye are still pending 15. A randomized controlled trial with a combination product of taurine and other substances found more favorable retinal values, but does not allow conclusions about taurine alone 35. It remains open whether taurine alone acts on the eye.

What side effects are known?

The included studies predominantly report no or only mild side effects, such as gastrointestinal complaints 232350. In a randomized controlled trial, mild adverse events occurred in some of the participants 23. Long-term safety is still insufficiently studied.

Can taurine improve blood sugar?

Several meta-analyses found lower fasting blood sugar with oral taurine, and in people with diabetes also lower long-term blood sugar and less insulin resistance 12813. In two randomized controlled trials in type 2 diabetes, fasting blood sugar, insulin and insulin resistance decreased more than with placebo 3132. A third study found a benefit only for insulin and insulin resistance, not for blood sugar 25. The findings come predominantly from powder or capsule administration in patients with metabolic disorders.

Sources

  1. 1
  2. 2
  3. 3
    Tzang CC, Lin WC, Lin LH, Lin TY, Chang KV, Wu WT et al. · 2024
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
    The effect of taurine supplementation on markers of muscle damage and muscle pain in an athletic population: A systematic review and meta-analysis of randomized controlled trials assessed using the grading of recommendations, assessment, development, and evaluation approach
    Dehghani E, Naeini F, Bidar SS, Beba M, Mortezapour E, Nourian R et al. · 2025
  11. 11
  12. 12
    Waldron M, Patterson SD, Tallent J, Jeffries O · 2018
  13. 13
  14. 14
    Roberts AT, Makar J, Abdelmalak J, Sinclair M, Testro A, Majumdar A · 2025
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
    Almeida CC, Mendonça Pereira BF, Leandro KC, Costa MP, Spisso BF, Conte-Junior CA · 2021
  21. 21
    Kurtz JA, VanDusseldorp TA, Doyle JA, Otis JS · 2021
  22. 22
  23. 23
    Sasidharan S, Philips CA, Philips CA, Tharakan A, Ahamed R, Oommen TT et al. · 2026
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney Disease
    Sengupta P, Biswas S, Roy T · 2022
  29. 29
  30. 30
    Vidot H, Cvejic E, Carey S, Strasser SI, McCaughan GW, Allman-Farinelli M et al. · 2018
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    Samadpour Masouleh S, Bagheri R, Ashtary-Larky D, Cheraghloo N, Wong A, Yousefi Bilesvar O et al. · 2021
  37. 37
    Islambulchilar M, Asvadi I, Sanaat Z, Esfahani A, Sattari M · 2015
  38. 38
  39. 39
    Islambulchilar M, Asvadi I, Sanaat Z, Esfahani A, Sattari M · 2015
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
    Lak S, Ostadrahimi A, Nagili B, Asghari-Jafarabadi M, Beigzali S, Salehi F et al. · 2015
  45. 45
  46. 46
  47. 47
    Abud GF, De Carvalho FG, Batitucci G, Travieso SG, Bueno Junior CR, Barbosa Junior F et al. · 2022
  48. 48
  49. 49
    Batitucci G, Brandao CFC, De Carvalho FG, Marchini JS, Pfrimer K, Ferrioli E et al. · 2019
  50. 50
    Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B et al. · 2018
  51. 51
    da Silva LA, Tromm CB, Bom KF, Mariano I, Pozzi B, da Rosa GL et al. · 2014
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
    Moloney MA, Casey RG, O'Donnell DH, Fitzgerald P, Thompson C, Bouchier-Hayes DJ · 2010
  66. 66
  67. 67
  68. 68
    Mottaghi S, Nikoupour H, Firoozifar M, Jalali SS, Jamshidzadeh A, Vazin A et al. · 2022
  69. 69
  70. 70
  71. 71
    Van Stijn MF, Bruins AA, Vermeulen MA, Witlox J, Teerlink T, Schoorl MG et al. · 2015
  72. 72
    Chupel MU, Minuzzi LG, Furtado G, Santos ML, Hogervorst E, Filaire E et al. · 2018
  73. 73
    Carvalho MB, Brandao CFC, Fassini PG, Bianco TM, Batitucci G, Galan BSM et al. · 2020
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
    van Vugt M, Finan C, Chopade S, Providencia R, Bezzina CR, Asselbergs FW et al. · 2024
  80. 80
    Post A, Said MY, Gomes-Neto AW, van der Krogt J, de Blaauw P, Berger SP et al. · 2019
  81. 81
    Marcangeli V, Cefis M, Hammad R, Granet J, Leduc-Gaudet JP, Gaudreau P et al. · 2025
  82. 82
  83. 83
  84. 84
  85. 85
    Kotb RR, Afifi AM, El-Houseini ME, Ezz-Elarab M, Basalious EB, Omran MM et al. · 2023
  86. 86
  87. 87
  88. 88
  89. 89
    Verzì AE, Nasca MR, Dall'Oglio F, Cosentino C, Micali G · 2021
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
    Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H et al. · 2019
  95. 95
  96. 96
    Rikimaru M, Ohsawa Y, Wolf AM, Nishimaki K, Ichimiya H, Kamimura N et al. · 2012
  97. 97
    Yoshida R, Mitsuno R, Nakayama T, Azegami T, Hashiguchi A, Torimitsu T et al. · 2025
  98. 98
  99. 99
    Frascatani R, Mattogno A, Salvatori S, Iannucci A, Marafini I, Monteleone G · 2026
  100. 100
    di Vito R, Hassan A, Nuzzo T, Caretto A, Panicucci C, Bruno C et al. · 2026
  101. 101
    Ullah M, Rehman AU, Shetty M, Allen MD, Ullah E, Signorini SG et al. · 2026
  102. 102
  103. 103
    Zhang N, Borné Y, Hagberg E, Palmqvist S, Glans I, Ottosson F et al. · 2025
  104. 104
  105. 105
    Sayedyousef H, Yilmaz O, Ozturk C, Demir B, Toygar HU, Balci N · 2025
  106. 106
    Khoramjoo M, Wang K, Srinivasan K, Gheblawi M, Mandal R, Rousseau S et al. · 2024
  107. 107
  108. 108
  109. 109
    Mahmoodpoor A, Farjami A, Farzan N, Hamishehkar H, Asgharian P, Sanaie S et al. · 2023
  110. 110
  111. 111
  112. 112
    Sak D, Erdenen F, Müderrisoglu C, Altunoglu E, Sozer V, Gungel H et al. · 2019
  113. 113
    Spelbrink EM, Mabud TS, Reimer R, Porter BE · 2016
  114. 114
    Tesiram YA, Lerner M, Stewart C, Njoku C, Brackett DJ · 2012
  115. 115
    Chiarla C, Giovannini I, Siegel JH, Boldrini G, Castagneto M · 2000
  116. 116
  117. 117
  118. 118
  119. 119
    Mirzohreh ST, Ghaffari S, Mesri Alamdari N, Banisefid E, Ghaffari M, Shabestari AN et al. · 2026
  120. 120
  121. 121
  122. 122
  123. 123
  124. 124
  125. 125
    Zanza C, Longhitano Y, Planinsic R, Voza A, Tesauro M, Caputo G et al. · 2026
  126. 126
    Bjørklund G, Izmailovich M, Nurpeissov T, Glushkova N, Semenova Y · 2026
  127. 127
  128. 128
  129. 129
  130. 130
    Fogagnolo C, Ortiz GU, Travieso SG, Rossini-Venturini AC, Abud GF, Silva BM et al. · 2025
  131. 131
    Beretta V, Scarpa E, Carloni S, Petrolini C, Dell'Orto V, Ravenda S et al. · 2025
  132. 132
  133. 133
    García-Ayuso D, Di Pierdomenico J, Martínez-Vacas A, Vidal-Sanz M, Picaud S, Villegas-Pérez MP · 2024
  134. 134
  135. 135
  136. 136
  137. 137
  138. 138
    Castelli V, Paladini A, d'Angelo M, Allegretti M, Mantelli F, Brandolini L et al. · 2021
  139. 139
  140. 140
  141. 141
    Hussain T, Tan B, Murtaza G, Metwally E, Yang H, Kalhoro MS et al. · 2020
  142. 142
  143. 143
  144. 144
    Spriet LL, Whitfield J · 2015
  145. 145
    Role of taurine in the vasculature: an overview of experimental and human studies
    Abebe W, Mozaffari MS · 2011
  146. 146
    Taurine and glucose metabolism: a review
    De la Puerta C, Arrieta FJ, Balsa JA, Botella-Carretero JI, Zamarrón I, Vázquez C · 2010

Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.

International Health Research · https://ih-research.com/en/knowledge/taurine/ · Last updated: 2026-10-15